SCHEMBL5653201

SCHEMBL5653201

CCN(CC)CCCNC(=O)c1ccc(-c2nc3c(C)c(C)c(Br)cc3[nH]2)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.48
WDR77 Q9BQA1 1/20 0.48
TMEM97 Q5BJF2 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
HTT P42858 3/20 0.42
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HPSE Q9Y251 1/20 0.40
ALDH1A1 P00352 2/20 0.39
RECQL P46063 1/20 0.39
TLR9 Q9NR96 1/20 0.39
TLR8 Q9NR97 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
IGF1R P08069 1/20 0.39
CYP1A2 P05177 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652439 0.93 HPSE (0.44) PRMT5WDR77HTTGAAKDM4E
SCHEMBL5649826 0.91 GAA (0.43) PRMT5WDR77HTTGAAKDM4E
SCHEMBL5648656 0.90 GAA (0.42) PRMT5WDR77HTTGAAKDM4E
SCHEMBL5652799 0.88 GAA (0.41) PRMT5WDR77HTTGAAKDM4E
SCHEMBL5651998 0.88 FLT3 (0.45) HTTHPSEMAPTMEN1LMNA
SCHEMBL5653197 0.87 PRMT5 (0.48) PRMT5WDR77TMEM97SIGMAR1HTT
SCHEMBL5652552 0.85 HDAC6 (0.44) PRMT5WDR77HTTGAAKDM4E
SCHEMBL5648995 0.83 PRMT5 (0.49) PRMT5WDR77TMEM97SIGMAR1HTT
SCHEMBL5651713 0.82 CYP2D6 (0.59) KDM4EALDH1A1RECQLCYP2D6CYP2C9
SCHEMBL5649922 0.81 HPSE (0.46) HPSETP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 PRMT5 448/4885WDR77 1101/4885TMEM97 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.